Platinum-based chemotherapy drug candidate trans,trans,trans-[Pt(N3)2(OH)2(py)2] study conducted by the Monash Warwick Alliance represented by various research groups from the University of Warwick and Monash University pioneered a new treatment option by triggering the cancer drug with infrared light. The resistance shown by the current cancer treatments make this light-activation cancer therapy, a turning point in the field of chemotherapy.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer